Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1278-1287

  Hu, Leijun ^a   Au, Jessie L S ^a,b   Wientjes, M Guillaume ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b College of Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ANIMAL EXPERIMENT; ARTICLE; CARDIOTOXICITY; CELL DEATH; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE DISEASE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COMPUTER SIMULATION; DOGS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS;

EID: 33947271469     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1610     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Barsanti JA. Diseases of the prostate gland. In: Osborne CA, Finco DR, editors. Canine and feline nephrology and urology. Baltimore: Williams & Wilkins: 1995. p. 726-58.
3. Bartsch G, Rohr HP. Comparative light and electron microscopic study of the human, dog and rat prostate. An approach to an experimental model for human benign prostatic hyperplasia (light and electron microscopic analysis) - a review. Urol Int 1980;35:91-104.
4. Inaba T. Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J Urol 1992;148:1457-60.
5. Andersson L, Dahn I, Nelson CE, Norgren A. Method for measuring prostatic blood flow with xenon-133 in the dog. Invest Urol 1967;5:140-8.
6. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci 1971;60:1128-33.
7. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, Inc.; 1982.
8. Harris PA, Gross JF. Preliminary pharmacokinetic model for Adriamycin (NSC-123127). Cancer Chemother Rep 1975;59:819-25.
9. Himmelstein KJ, Lutz RJ. A review of the applications of physiologically based pharmacokinetic modeling. J Pharmacokinet Biopharm 1979;7:127.
10. King FG, Dedrick RL. Physiologic model for the pharmacokinetics of 2′deoxycoformycin in normal and leukemic mice. J Pharmacokinet Biopharm 1981;9:519-34.
11. Myers CE, Chabner BA. Anthracyclines. In: Chabner BA, Collins JM, editors. Cancer chemotherapy: principles and practice. Philadelphia: Lippincott; 1990. p. 356-81.
12. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15-31.
13. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
14. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997;13:407-84.
15. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5.
16. Zetterstrom BE. Evaluation of the 133 Xenon clearance method for measurement of blood flow in the dog spleen. Acta Chir Scand 1973;139:27-33.
17. Lima JJ, MacKichan JJ, Libertin N, Sabino J. Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation. J Pharmacokinet Biopharm 1983;11:483-98.
18. Terasaki T, Iga T, Sugiyama Y, Hanano M. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J Pharm Sci 1984;73:1359-63.
19. Dooley MJ, Poole SG. Poor correlation between body surface area and glomerular filtration rate. Cancer Chemother Pharmacol 2000;46:523-6.
20. Ung JO, San Francisco IF, Began MM, DeWolf WC, Olumi AF. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol 2003;169:130-5.
21. Sech S, Montoya J, Girman CJ, Rhodes T, Roehrborn CG. Interexaminer reliability of transrectal ultrasound for estimating prostate volume. J Urol 2001;166:125-9.
22. Stephan C, Cammann H, Semjonow A, et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48:1279-87.
23. Eksborg S, Strandler HS, Edsmyr F, Naslund I, Tahvanainen P. Pharmacokinetic study of i.v. infusions of Adriamycin. Eur J Clin Pharmacol 1985;28:205-12.
24. Chai M, Wientjes MG, Badalament RA, Burgers JK, Au JL. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 1994;152:374-8.
25. Shinkai H, Takahashi H, Miyamoto K, Uchida T, Tokiwa T. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice. Cancer Chemother Pharmacol 1996;38:417-24.
26. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
27. Chen CT, Gan Y, Au JL, Wientjes MG. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res 1998;58:2777-83.
28. Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993;32:255-62.
29. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604.
30. Au JL, Badalament RA, Wientjes MG, et al. Optimized intravesical mitomycin C treatment for superficial bladder cancer: long-term follow-up. J Urol 2006;175:268.
31. Gallo JM, Hung CT, Gupta PK, Perrier DG. Physiological pharmacokinetic model of Adriamycin delivered via magnetic albumin microspheres in the rat. J Pharmacokinet Biopharm 1989;17:305-26.
32. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Evidence of a specific complex between Adriamycin and negatively charged phospholipids. Biochim Biophys Acta 1980;597:1-14.
33. Mustonen P, Kinnunen PK. On the reversal by deoxyribonucleic acid of the binding of Adriamycin to cardiolipin-containing liposomes. J Biol Chem 1993;268:1074-80.
34. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 2002;91:1488-501.
35. Kawai R, Lemaire M, Steimer JL, Bruelisauer A, Niederberger W, Rowland M. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 1994;22:327-65.
36. Kawai R, Mathew D, Tanaka C, Rowland M. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 1998;287:457-68.
37. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991;19:21-50.
38. Chen CT, Au JL, Gan Y, Wientjes MG. Differential time dependency of antiproliferative and apoptotic effects of Taxol in human prostate tumors. Urol Oncol 1997;3:11-7.
39. Schmittgen TD, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res 1991;51:3849-56.
40. El Yazigi A, Berry J, Ezzat A, Wahab FA. Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. Ther Drug Monit 1997;19:632-6.
41. Chen CT, Au JL, Wientjes MG. Pharmacodynamics of doxorubicin in human prostate tumors. Clin Cancer Res 1998; 4: 277-82.